- Home
- MYGN vs AMC Comparison
MYGN vs AMC Comparison
Compare MYGN & AMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- AMC
- Stock Information
- Founded
- MYGN 1991
- AMC 1920
- Country
- MYGN United States
- AMC United States
- Employees
- MYGN N/A
- AMC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AMC Movies/Entertainment
- Sector
- MYGN Health Care
- AMC Consumer Discretionary
- Exchange
- MYGN Nasdaq
- AMC Nasdaq
- Market Cap
- MYGN 2.0B
- AMC 1.6B
- IPO Year
- MYGN 1995
- AMC 2013
- Fundamental
- Price
- MYGN $13.50
- AMC $4.02
- Analyst Decision
- MYGN Hold
- AMC Sell
- Analyst Count
- MYGN 11
- AMC 5
- Target Price
- MYGN $24.27
- AMC $4.30
- AVG Volume (30 Days)
- MYGN 1.1M
- AMC 17.5M
- Earning Date
- MYGN 02-25-2025
- AMC 02-26-2025
- Dividend Yield
- MYGN N/A
- AMC N/A
- EPS Growth
- MYGN N/A
- AMC N/A
- EPS
- MYGN N/A
- AMC N/A
- Revenue
- MYGN $823,600,000.00
- AMC $4,435,200,000.00
- Revenue This Year
- MYGN $13.82
- AMC N/A
- Revenue Next Year
- MYGN $4.59
- AMC $11.07
- P/E Ratio
- MYGN N/A
- AMC N/A
- Revenue Growth
- MYGN 12.15
- AMC N/A
- 52 Week Low
- MYGN $12.87
- AMC $2.38
- 52 Week High
- MYGN $29.30
- AMC $11.88
- Technical
- Relative Strength Index (RSI)
- MYGN 32.61
- AMC 39.39
- Support Level
- MYGN $13.04
- AMC $3.98
- Resistance Level
- MYGN $13.77
- AMC $4.15
- Average True Range (ATR)
- MYGN 0.60
- AMC 0.17
- MACD
- MYGN 0.14
- AMC -0.02
- Stochastic Oscillator
- MYGN 24.51
- AMC 25.00
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, premium presentation. The Company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.